GLP-1 & compounded medication availability in New Mexico (2026)

New Mexico’s regulators have been unusually direct about weight-loss medications. The state’s own consumer-protection authority published an alert in late 2025 telling residents exactly how to buy them safely: real provider, real prescription, state-licensed pharmacy. That is a description of how OrderlyMeds works. Below, all ten product lines we track for New Mexico addresses, with the state’s actual published positions, cited.

Baseline state

Availability facts last reviewed: November 16, 2026

What ships to New Mexico: all ten lines

Availability of all ten OrderlyMeds product lines in New Mexico, with typical delivery times and notes
Product lineAvailable in New Mexico?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Ships to New Mexico under a patient-specific prescription.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days The national price is the New Mexico price.
NAD+ Yes 8–10 business days Longevity line, ordered through the same flow.
Sermorelin Yes 8–10 business days Ships from licensed partner pharmacies.
Glutathione No N/A Not currently an OrderlyMeds product.
BPC-157 Yes 8–10 business days A formulary injectable. Federal record below.
TB-500 Yes 8–10 business days A formulary injectable; see the section below.
KPV No N/A Not in the formulary, because these lines are injectables only and KPV is not.
Epitalon Yes 8–10 business days A formulary injectable; its federal picture is below.
MOTS-c Yes 8–10 business days A formulary injectable with its own distinct federal record, below.

We print the “No” rows because leaving them out would be the misleading choice. New Mexico facts last reviewed November 16, 2026.

Research peptides in New Mexico: BPC-157, TB-500, KPV, Epitalon & MOTS-c

In New Mexico as everywhere we operate, four of these five are formulary lines: BPC-157, TB-500, Epitalon and MOTS-c, compounded as injectables under patient-specific prescriptions. KPV is not, because we compound these lines as injectables only. Each line’s federal record follows, stated identically whether the row above says yes or no.

BPC-157 in New Mexico

A formulary injectable for New Mexico, dispensed on a patient-specific prescription. The federal facts below apply without exception.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in New Mexico

Ships to New Mexico as a compounded injectable under a patient-specific prescription; its record is below.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in New Mexico

Not dispensed in New Mexico, or in any state. We compound these lines as injectables, and KPV is not one of them.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in New Mexico

Available to New Mexico patients as a compounded injectable on a patient-specific prescription. Nothing below is changed by that.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in New Mexico

Carried for New Mexico as a compounded injectable, on a patient-specific prescription. Its federal record is its own; the section states it as such.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What New Mexico’s pharmacy regulators say about compounded medications

New Mexico pairs standard pharmacy licensure with an unusually vocal consumer-protection posture: the licensing side runs through the state’s Regulation and Licensing Department, and the consumer side spoke up directly about weight-loss medications in 2025. For a New Mexico patient, both point the same direction: a real evaluation, a prescription in your name, and a pharmacy the state licenses.

Out-of-state pharmacies shipping prescription drugs to New Mexico patients must hold a nonresident pharmacy license from the New Mexico Board of Pharmacy, and distribution of non-patient-specific compounded product into the state is restricted — the compliant path is a prescription written for a specific patient. Source: New Mexico Board of Pharmacy (Regulation and Licensing Department).

On October 31, 2025, the New Mexico Department of Justice issued a consumer alert on weight-loss medications, urging residents to consult a licensed healthcare provider, obtain a valid prescription, and fill it only at a state-licensed pharmacy — and cautioning against sellers offering these medications any other way. Source: New Mexico Department of Justice — weight-loss medication alert.

New Mexico permits care, including prescribing, through telehealth encounters in which a history is taken, informed consent is obtained, and a medical record is generated; the state also issues a dedicated telemedicine license to qualifying out-of-state physicians. Source: CCHP Policy Finder — New Mexico.

A New Mexico order is the alert’s checklist in practice: a licensed provider evaluates you by telehealth, writes a prescription in your name if appropriate, and a state-licensed nonresident partner pharmacy fills and ships it. Pricing is national at every dose, so the published price is the New Mexico price.

New Mexico availability FAQs

Is compounded semaglutide available in New Mexico?

Yes. It ships to New Mexico addresses under a patient-specific prescription, at the national price of $74/month for the first two months for new customers.

What does New Mexico's weight-loss medication alert mean for me?

The state's consumer-protection authority says to use a licensed provider, a valid prescription, and a state-licensed pharmacy. That is the OrderlyMeds flow by construction, and the alert itself is cited in the regulator section above.

Do I need an in-person visit to get started in New Mexico?

No. A telehealth evaluation with a provider licensed for New Mexico is how care starts; the cited detail is in the regulator section above.

Can I get BPC-157 or other research peptides shipped to New Mexico?

Yes to BPC-157, TB-500, Epitalon and MOTS-c, as compounded injectables on patient-specific prescriptions. No to KPV, in any state. Each line's federal record is stated above.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone